Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
RECRUITING
NCT04322890
PHASE2

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Sponsor: Hunan Province Tumor Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Official title: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

6000

Start Date

2020-04-16

Completion Date

2027-12-24

Last Updated

2024-10-22

Healthy Volunteers

No

Conditions

Non Small Cell Lung CancerEGFR Gene MutationALK Gene MutationROS1 Gene MutationMET Gene Mutation

Interventions

DRUG

Osimertinib

Osimertinib 80mg, po, qd;

DRUG

Alectinib 150 MG

Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;

DRUG

Crizotinib 250 MG

Crizotinib 250 MG po bid.

DRUG

Savolitinib, Crizotinib.

Savolitinib, 300mg po qd.

DRUG

Chemotherapy

500mg, ivgtt, every 21day.

Locations (1)

Yongchang Zhang

Changsha, Hunan, China